EquityFlow
›
Companies
› Apollo Therapeutics
Apollo Therapeutics
Biotech
· Cambridge, GB
Biopharma translating university research into medicines.
Funding history
Date
Round
Amount
Jan 2024
Series C
Cambridge biopharma Apollo Therapeutics added $33.5M in a second close of its Series C (now $260M total) led by Patient Square Capital.
$33.5M
Investors
M&G
Patient Square Capital
Rock Springs Capital
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →